{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:41:38Z","timestamp":1785832898979,"version":"3.56.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI139768"],"award-info":[{"award-number":["AI139768"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["EY024710"],"award-info":[{"award-number":["EY024710"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.biopha.2023.115056","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:28:06Z","timestamp":1688430486000},"page":"115056","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tolerability, pharmacokinetics, and anti-herpetic activity of orally administered BX795"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8584-2685","authenticated-orcid":false,"given":"Tejabhiram","family":"Yadavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0376-110X","authenticated-orcid":false,"given":"Sudhanshu Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit A.","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3039-6953","authenticated-orcid":false,"given":"Deepak","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115056_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00003226-200101000-00001","article-title":"Herpes simplex virus epidemiology and ocular importance","volume":"20","author":"Liesegang","year":"2001","journal-title":"Cornea"},{"key":"10.1016\/j.biopha.2023.115056_bib2","first-page":"16","volume":"2019","author":"Rozenberg","year":"2011","journal-title":"Herpes Simple Enceph.: Virus Ther."},{"key":"10.1016\/j.biopha.2023.115056_bib3","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ajo.2005.10.008","article-title":"Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy","volume":"141","author":"Pepose","year":"2006","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2023.115056_bib4","doi-asserted-by":"crossref","first-page":"973","DOI":"10.7326\/0003-4819-98-6-958","article-title":"Genital herpes simplex virus infections: current concepts in diagnosis, therapy, and prevention","volume":"98","author":"Corey","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2023.115056_bib5","first-page":"381","article-title":"The epidemiology of herpes simplex types 1 and 2 infection of the genital tract in Edinburgh 1978-1991","volume":"69","author":"Ross","year":"1993","journal-title":"Genitourin. Med"},{"key":"10.1016\/j.biopha.2023.115056_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.OLQ.0000093080.55201.D1","article-title":"Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes?","volume":"30","author":"Mertz","year":"2003","journal-title":"Sex. Transm. Dis."},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2023.115056_bib7","article-title":"Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir","volume":"186","author":"Tyring","year":"2002","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2023.115056_bib11","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0166-3542(84)90014-7","article-title":"Antiviral medications and corneal wound healing","volume":"4","author":"Lass","year":"1984","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2023.115056_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5861","article-title":"An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye","volume":"10","author":"Jaishankar","year":"2018","journal-title":"Sci. Transl. Med"},{"key":"10.1016\/j.biopha.2023.115056_bib13","doi-asserted-by":"crossref","first-page":"14136","DOI":"10.1074\/jbc.M109.000414","article-title":"Use of the pharmacological inhibitor bx795 to study the regulation and physiological roles of TBK1 and I\u03baB kinase \u03b5","volume":"284","author":"Clark","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115056_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105145","article-title":"Prophylactic treatment with BX795 blocks activation of AKT and its downstream targets to protect vaginal keratinocytes and vaginal epithelium from HSV-2 infection","volume":"194","author":"Madavaraju","year":"2021","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2023.115056_bib15","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00245-20","article-title":"In vitro and in vivo activity, tolerability, and mechanism of action of BX795 as an antiviral against herpes simplex virus 2 genital infection","volume":"64","author":"Hopkins","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2023.115056_bib16","article-title":"Prior inhibition of AKT phosphorylation by BX795 can define a safer strategy to prevent herpes simplex virus-1 infection of the eye","author":"Yadavalli","year":"2019","journal-title":"Ocul. Surf."},{"key":"10.1016\/j.biopha.2023.115056_bib17","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1136\/bjo.2008.138065","article-title":"Comparison of oral antiviral therapy with valacyclovir or acyclovir after penetrating keratoplasty for herpetic keratitis","volume":"92","author":"Goldblum","year":"2008","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2023.115056_bib18","first-page":"870","article-title":"Complete genome sequence of herpes simplex virus 2","volume":"7","author":"L\u00f3pez-Mu\u00f1oz","year":"2018","journal-title":"Strain 333. Microbiol Resour. Announc"},{"key":"10.1016\/j.biopha.2023.115056_bib19","doi-asserted-by":"crossref","first-page":"9540","DOI":"10.1128\/JVI.01469-12","article-title":"Genome sequence of herpes simplex virus 1 strain McKrae","volume":"86","author":"Macdonald","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.biopha.2023.115056_bib20","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd9443","article-title":"Standalone or combinatorial phenylbutyrate therapy shows excellent antiviral activity and mimics CREB3 silencing","volume":"6","author":"Yadavalli","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.biopha.2023.115056_bib21","doi-asserted-by":"crossref","DOI":"10.3791\/62195","article-title":"Porcine corneal tissue explant to study the efficacy of herpes simplex virus-1 antivirals","author":"Yadavalli","year":"2021","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2023.115056_bib22","doi-asserted-by":"crossref","first-page":"63","DOI":"10.4049\/jimmunol.2100472","article-title":"Intrinsic antiviral activity of optineurin prevents hyperproliferation of a primary herpes simplex virus type 2 infection","volume":"208","author":"Patil","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.biopha.2023.115056_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0166-3542(95)00066-6","article-title":"Valacyclovir: a review of its antiviral activity, pharmacokinetic properties, and clinical efficacy","volume":"28","author":"Beutner","year":"1995","journal-title":"Antivir. Res"},{"key":"10.1016\/j.biopha.2023.115056_bib24","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003495-198223050-00001","article-title":"Trifluridine: a review of its antiviral activity and therapeutic use in the topical treatment of viral eye infections","volume":"23","author":"Carmine","year":"1982","journal-title":"Drugs"},{"key":"10.1016\/j.biopha.2023.115056_bib25","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1080\/08820530802111085","article-title":"Ocular HSV-1 latency, reactivation and recurrent disease","volume":"23","author":"Toma","year":"2008","journal-title":"Semin Ophthalmol."},{"key":"10.1016\/j.biopha.2023.115056_bib26","doi-asserted-by":"crossref","first-page":"958","DOI":"10.7326\/0003-4819-98-6-958","article-title":"Genital herpes simplex virus infections: clinical manifestations, course, and complications","volume":"98","author":"Corey","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.biopha.2023.115056_bib27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1002\/1873-3468.12176","article-title":"The TBK1-binding domain of optineurin promotes type I interferon responses","volume":"590","author":"Meena","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2023.115056_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108234","article-title":"Evasion of Type I Interferon by SARS-CoV-2","volume":"33","author":"Xia","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.biopha.2023.115056_bib29","article-title":"Optineurin functions for optimal immunity","volume":"0","author":"Slowicka","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.biopha.2023.115056_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bcp.2018.06.010","article-title":"Evaluating the intestinal and oral absorption of the prodrug valacyclovir in wildtype and huPepT1 transgenic mice","volume":"155","author":"Epling","year":"2018","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2023.115056_bib31","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1128\/AAC.01803-12","article-title":"Pharmacokinetics and pharmacodynamics of ASP2151, a helicase-primase inhibitor, in a murine model of herpes simplex virus infection","volume":"57","author":"Katsumata","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.biopha.2023.115056_bib32","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.3390\/pharmaceutics13111920","article-title":"BX795-organic acid coevaporates: evaluation of solid-state characteristics, in vitro cytocompatibility and in vitro activity against HSV-1 and HSV-2","volume":"13","author":"Sutar","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223008466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:08:12Z","timestamp":1777878492000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223008466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":29,"alternative-id":["S0753332223008466"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115056","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability, pharmacokinetics, and anti-herpetic activity of orally administered BX795","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115056"}}